- Nineteen prisoners use cutlery to break out of cells at Winchester prison
- France wants progress in Ukraine before Russia returns to G7
- Italy president begins talks to seek way out of government crisis
- Italian PM expected to resign as political chaos deepens
- Russia says US cruise missile test ‘regrettable’
- Kremlin - No date set for Normandy talks on Ukraine despite Macron meeting
- Egypt court hands out 6 death sentences on terror charges
- Putin says Russian nuclear explosion poses no threat
- Russian panel eyes alleged foreign interference in protests
- Gran Canaria wildfire triggers evacuation of thousands of people
- PM Johnson calls on Germany and France to compromise on Brexit
- Sudan's ex-president Bashir arrives at corruption trial
TEHRAN, Sept 27-Johns Hopkins University researchers plan to use psychedelic drugs to attack some of society's toughest problems at a new research center, including smoking, depression, alcoholism, Alzheimer's disease, anorexia, Lyme disease and even addiction to opioids.
TEHRAN, Young Journalists Club(YJC)_Private donations of $17 million have been pledged for the new Center for Psychedelic & Consciousness Research, which opened this month in Baltimore.
For almost 20 years, a small group of scientists have been studying mind-altering drugs and their potential to unlock the human mind after research screeched to a halt in the 1970s during the Nixon administration.
"It's incredibly exciting as the largest single donation or investment into psychedelic research," said Brad Burge, director of strategic communications for the San Francisco-based non-profit Multidisciplinary Association for Psychedelic Studies.
"This donation shows that there will be enough regulation and public support that will create jobs in research and therapy. This research has moved out of the fringe."
Along with a U.S. movement to decriminalize "magic mushrooms," which contain the psychedelic drug psilocybin, dedicated groups of researchers have been studying the therapeutic mental health benefits of psychedelics such as LSD, MDMA (also known as the street drug Ecstasy or Molly) and ketamine.
Source of funding
Private funding for the new center comes from the Steven & Alexandra Cohen Foundation and a handful of philanthropists: business author Tim Ferriss; Matt Mullenweg, co-founder of WordPress; TOMS Shoes founder Blake Mycoskie and investor Craig Nerenberg.
Over the past two decades, more than 350 subjects in 700 sessions have tried psychedelics at Johns Hopkins in carefully monitored settings, said Roland Griffiths, director of the new center.
But many of the studies have been on very small numbers of patients. For example, a 2016 study showed low doses of psilocybin reduced depression and anxiety in terminal cancer patients, but only involved 51 participants.
Magic mushrooms helped 85 percent of longtime smokers who participated in a Johns Hopkins therapeutic program, but only 15 subjects participated. The new funding will help expand this research to larger groups and also drive research into discovering how the drugs work.
Griffiths said in studies with psilocybin, researchers have found the drug can change character traits and make patients experience more altruism and openness.
"Under appropriate screening and setting conditions, we can occasion experiences that are felt to be personally significant and often the most meaningful of people's entire lifetimes," Griffiths told UPI. "For patients with depression and addiction issues, researchers have seen "remarkable and enduring changes," he said.
A patient in psilocybin research is given about eight hours of pre-dose counseling. During the treatment, the patient lies on a couch with an eye mask and headphones that play music. Two researchers stay with the patient during the entire six-hour trip.
source:upi
Your Comment